Novartis: Strong Execution With A P/E Discount
Novartis exceeds Q4 2024 expectations with 16% sales growth, strong EPS trajectory, and strategic R&D investments. Read why ...
stocknews22h
3 Gene Therapy Stocks With Game-Changing Potential
Gene therapy stocks are transforming healthcare with revolutionary treatments. Therefore, as this sector continues to evolve, ...
C&EN5d
Business briefing
Novartis will buy Anthos Therapeutics, a Boston-based biotech focused on cardiac conditions, for an up front payment of $925 million. Anthos was founded in 2019 by Novartis and the private equity ...
pharmaphorum2d
Bayer doubles down on Factor XIa with new phase 3 trial
Novartis has agreed to buy Anthos from private equity firm Blackstone for $3.1 billion, taking Factor XI inhibitor abelacimab back in-house.
pharmaphorum2d
Novartis adds another string to iptacopan’s bow
IgAN is a key focus for Novartis, driving a decision to acquire Chinook Therapeutics for $3.2 billion upfront earlier this year, adding a pair of late clinical-stage programmes for the disease ...